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ABSTRACT 
 
The human adenovirus serotype 35 (HAdV-35, short Ad35) causes kidney and urinary 
tract infections, and infects respiratory organs of immunocompromised individuals.  
Unlike other adenoviruses, Ad35 has a low seroprevalence which makes Ad35-based 
vectors promising candidates for gene therapy.  Ad35 utilizes CD46 and integrins as 
receptors for infection of epithelial and hematopoietic cells.  Here, we show that 
infectious entry of Ad35 into HeLa, human kidney HK-2 cells and normal human lung 
fibroblasts strongly depended on CD46 and integrins but not heparan sulfate, and 
variably required the large GTPase dynamin.  Ad35 infections were independent of 
expression of the carboxy-terminal domain of AP180 which effectively blocks clathrin-
mediated uptake.  Ad35 infections were inhibited by small chemicals against the 
serine/threonine kinase Pak1 (p21-activated kinase), protein kinase C (PKC), sodium-
proton exchangers, actin and acidic organelles.  Remarkably, the F-actin inhibitor 
jasplakinolide, the Pak1 inhibitor IPA-3 or the sodium-proton exchange inhibitor EIPA 
blocked the endocytic uptake of Ad35.  Dominant-negative proteins or small interfering 
RNAs against factors driving macropinocytosis, including the small GTPase Rac1, Pak1 
or the Pak1 effector C-terminal binding protein 1 (CtBP1) potently inhibited Ad35 
infection.  Confocal laser scanning microscopy, electron microscopy and live cell 
imaging showed that Ad35 colocalized with fluid phase markers in large endocytic 
structures that were positive for CD46, alpha v integrins and also CtBP1.  Our results 
extend earlier observations with HAdV-3 (Ad3), and establish macropinocytosis as an 
infectious pathway for species B human adenoviruses in epithelial and hematopoietic 
cells.  
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INTRODUCTION 
 
Adenoviruses circulate widely in the human population, and most adults have been 
exposed to adenoviruses (13).  Currently, there are more than 54 HAdV serotypes 
known, and they have partly divergent entry pathways (for taxonomic details, see 
http://www.vmri.hu/~harrach/AdVtaxlong.htm).  HAdVs are classified into six species A 
to F.  Clinical manifestations of HAdV vary considerably, but commonly include cold 
symptoms, pharyngitis, tonsilitis, otitis, and pharyngoconjunctival fever. Less common 
are severe pneumonia, conjunctivitis, cystitis, encephalitis and meningitis (50, 81).  In 
immunocompromised patients and young military recruits, HAdVs cause life-threatening 
infections (49).   
 
The entry of the species C HAdV-2 (Ad2) and HAdV-5 (Ad5) is best characterized.  
Ad2/5 bind to the coxsackie B virus-Ad receptor CAR (8), and use αν-integrins as 
secondary receptors to induce receptor-mediated endocytosis involving clathrin, clathrin 
adaptors and the large GTPase dynamin (31, 34, 63, 102, 105).  These viruses also 
trigger accessory dynamin-independent macropinocytosis, which is not used to 
internalize Ad2/5 into cultured cells (63).  Macropinocytosis is, however, an important 
infectious pathway into epithelial cells for the species B1 HAdV-3 (Ad3, 3).  It is also an 
entry pathway for an increasing number of viruses from other families, such as vaccinia 
virus (67), echovirus 1 (43), Kaposi sarcoma herpes simplex virus (83) and Ebola virus 
(82).  Macropinocytosis has been associated with human immunodeficiency virus 1 
(HIV) infections in different cell types (27, 58, 60), but dynamin-dependent endocytosis 
of HIV has also been reported (70).   
 
Macropinocytosis is a form of endocytosis occurring at large scale.  It leads to the 
formation of large vacuoles, predominantly at the cellular periphery (97).  It often but not 
always involves ruffling protrusions from the plasma membrane that either fuse with 
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themselves or with the cell membrane and thereby engulf extracellular material (21).  
Macropinocytosis significantly contributes to antigen presentation in immune cells (66, 
104), and is used by viral and bacterial pathogens to reduce immune responses (68, 
97).  
 
The small GTPase Rac1 and dynamic actin filaments invariably control 
macropinocytosis.  Macropinocytosis also strongly requires p21-activated kinase Pak1 
(20), which binds and activates Rac1 (46), and variably depends on 
phosphatidylinositol-3-kinase (PI3K), Ras, and Src activities downstream of activated 
receptors.  In addition, macropinocytosis requires the C-terminal binding protein 1 
(CtBP1), which is phosphorylated by Pak1 and supports membrane fission or 
stabilization of the emerging macropinosomal vesicle (35, 56).  It is strongly blocked by 
inibitors of sodium/proton exchangers (103), such as amiloride or an amiloride analogue 
EIPA (37), which decrease cytosolic pH and thereby inhibit the activation of Rac1 and 
Cdc42 GTPases in submembranous zones (48).  Another hallmark of macropinocytosis 
is the dependency on protein kinase C (PKC) in both macrophages and epithelial cells 
(4, 5, 63).   
 
Ad35 is a member of the species B2 adenoviruses, which use CD46 as a primary 
receptor in epithelial and hematopoietic cells (26, 30), and integrins as coreceptors for 
infection of hematopoietic cells (72).  This virus was initially isolated from kidney of an 
immunocompromised individual (73).  Species B2 adenoviruses naturally infect the 
kidney and urinary tracts, and are sometimes fatal in immunocompromised individuals, 
possibly due to reemergence from a latent state (38, 53).  In addition, Ad35 is a 
promising vector for clinical gene transfer and vaccination, in part due to the low 
seroprevalence of neutralizing antibodies in the population (101).  For example, an 
Ad35-based malaria vaccine was shown to protect mice from Plasmodium falciparum 
sporozoites (78), and induced potent T-cell immunity (84).  In addition, Ad35 vectors 
 5 
injected into tissues of nonhuman primates gave rise to specific gene expressions at 
sites of injection in most organs indicating the high versatility of Ad35 (87, 88).   
 
Here we examined the infectious entry pathway for Ad35 into human epithelial cells and 
human kidney 2 (HK-2) cells, and compared the results with host requirements for 
infectious entry of the species C Ad2/5.  Unlike Ad2/5, Ad35 uses macropinocytosis as 
an infectious uptake pathway.  It requires CD46, integrins, PKC, sodium/proton 
exchanger, actin, Rac1, Pak1 and CtBP1 but not heparan sulfate, which had been 
suggested to be involved in virus attachment to Chinese hamster ovary cells (99).  
These results mirror the infectious pathway into epithelial cells for the species B1 Ad3 
(3).  This is remarkable since Ad3 had been suggested to use other receptors besides 
CD46 (61, 95).  Notably, it was recently shown that Ad3 binds to the same region of the 
terminal short consensus repeat 1 (SCR1) and SCR2 of CD46 as Ad35, albeit with 
lower affinity than Ad35 (25, 26), and this leads to gene expression in high CD46-
expressing baby hamster kidney (BHK) cells, CHO cells or malignant glioma cells (36, 
95, 100).  Our results show that HAdVs of the species B1 and B2 use conserved entry 
pathways into epithelial cells which depend on CD46. 
 
 
 
MATERIALS AND METHODS 
 
Cells and viruses  
 
Normal diploid human embryonic lung-derived fibroblasts Wi-38 (CCL-75) were 
purchased from American Type Cell Culture Collection (ATCC) and grown in DMEM 
(Sigma) containing 10% FCS (Invitrogen).  HeLa-ATCC (CCL-2), HeLa-K, a variant of 
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HeLa-ATCC with particularly high transfection efficiencies was obtained from Dr. U. 
Kutay (Institute of Biochemistry, ETH Zurich, Switzerland).  Human melanoma M21, 
M21L and M21L4 cells were grown in DMEM (Sigma) containing 10 % FCS (Invitrogen) 
at low passage number as described (63).  M21 (positive for surface-expressed αν-
integrins), M21L cells (negative for αν-integrins) and M21L4 transfected with αν-integrin 
cDNA (24) were obtained from Dr. D. Cheresh (Scripps Research Institute, La Jolla, CA, 
USA).  Human kidney HK-2 cells originally isolated from kidney proximal tubular cells 
and immortalized with human papilloma virus 16 E6 and E7 proteins (86) was obtained 
from Dr. F. Verrey (Institute of Physiology, University of Zurich, Zurich), and propagated 
in K1-medium.  Human hematopoietic K562 cells were used as described (3).  CHO 
cells stably expressing GFP-CD46 were generated by transfection of CHO-15B6 cells 
with a pcDNA3.1-neo vector containing the CD46-BC1 sequence, and single clones 
were selected in G418 (1mg/ml) containing medium.  Ad35 was isolated from human 
bronchial epithelial A549 cells. Fluorescent tagging of Ad35 with Texas-Red (Molecular 
Probes, Leiden, The Netherlands) was performed as described (96).  Ad35-eGFP, Ad5-
eGFP and Ad2-ts1 were used as described (31, 74, 101).  HSV-1-eGFP was a kind gift 
from Dr. C. Fraefel (Institute of Veterinary Virology, University of Zurich,76).  3H-Ad35 
was generated as described in (33).   
 
 
Viral eGFP transduction experiments 
 
For infection analyses by wide-field microscopy or confocal laser scanning microscopy 
(CLSM) analyses cells were seeded onto glass coverslips in 24 well dishes.  
Alternatively, infection measurements were carried out in a Safire monochromator-
based microplate detection system (Tecan Group Ltd. Switzerland) using 96 well plates.  
Cells were infected with the indicated eGFP-expressing virus at a MOI 5 in warm 
DMEM-0.2% BSA (Sigma A9418) for 60 min, washed twice with warm DMEM-0.2% 
BSA and further incubated for 7 h, fixed in 3% paraformaldehyde for 25 min, quenched 
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with ammonium chloride and prepared for analysis as indicated above.  Chemical 
interference with infection was performed by addition of compounds 30 min prior to 
infection in DMEM-0.2% BSA at 37°C.  Cells were infected in the presence of the 
inhibitors in DMEM-0.2% BSA for 60 min, washed twice and further incubated for 7 h.  
 
 
cDNAs, antibodies and chemicals 
 
Human K44A-Dyn2 and Dyn2 expression constructs were obtained from Dr. C. Lamaze 
(Pasteur Institute, Paris, France).  Plasmids expressing human Rac1 and T17N-Rac1 
were from Dr. A. Hall (University College, London, UK).  Expression plasmids encoding 
CtBP1-S (obtained from Dr. A. Colanzi and Dr. A. Luini, Department of Cell Biology and 
Oncology, Sta Maria Imbaro, Italy) were used to construct myc-tagged CtBP1 and 
S147A-CtBP1 (3).  Pak1 and Pak1 autoinhibitory domain (AID) constructs were 
obtained from Dr. J. Chernoff (Fox Chase Cancer Center, Philadelphia, PA, USA).  The 
following antibodies and chemicals were purchased as follows: anti-CtBP1 (BD-
Transduction Laboratories, Switzerland), anti-CD46 E4.3 (monoclonal, BD-Pharmingen, 
used for immunofluorescence analyses), anti-CD46 (polyclonal H-294, Santa Cruz, for 
Western blots), anti-CD46 (monoclonal MEM-258, used for inhibition 
experiments, Serotec Ltd, Oxford, United Kingdom), anti-αν β5 integrin (P1F6, 
monoclonal, Chemicon).  Secondary antibodies were goat anti-mouse or anti-rabbit 
coupled to Cy5 (Pierce).  The dynamin inhibitor dynasore (59) was purchased from 
Sigma and dissolved in DMSO.  Latrunculin was from Enzo Life Sciences, and cyclic 
tripeptide arginine-glycine-aspartate (single amino acid code cRGD) and cRAD (alanine 
substitution for glycine) peptides were obtained from Peptides International.  The PKC 
inhibitor Gö6976, the sodium/proton exchanger inhibitor EIPA, cytochalasin D and 
jasplakinolide were from Calbiochem.  The Pak1 inhibitor IPA-3 and its inactive 
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analogon PIR3.5 were obtained from Dr. J. Peterson (Basic Science Division, Fox 
Chase Cancer Center, Philadelphia, USA) (19).   
 
 
siRNA transfections 
 
HeLa-ATCC, HK-2 and A549 cells were transfected with 20 or 50 nM siRNA for 72 h or 
as indicated using Lipofectamine 2000 (Invitrogen) and the following siRNA.  Validated 
siRNAs were used against CtBP1 (GGAUAGAGACCACGCCAGUUU, Qiagen, (9)) and 
Pak1 (Qiagen, cat. no. SI00605696), against eGFP (Qiagen, No:1022064), CD46 
(Qiagen, as described by 30), and non-silencing scrambled siRNA 
(AGGUAGUGUAAUCGCCUUG dTdT, Microsynth, Switzerland). Clathrin heavy-chain 
(AACCUGCGGUCUGGAGUCAAC, Qiagen, (63). Dynamin2 
(GACAUGAUCCUGCAGUUCA, Qiagen). K562 cells were transfected with the indicated 
siRNA using Nucleofector I (Amaxa, Germany). 
 
 
Microscopy 
 
Spinning disc live cell microscopy images were recorded with a UplanApo100X 
objective (NA 1.35) on an Olympus IX81 inverted microscope (Olympus) equipped with 
a Yokogawa scanning head QLC100 (Visitron Systems GmbH, Puchheim, Germany), 
containing a triple bandpass excitation filter (488 nm/565 nm/647 nm, Chroma), and a 
NV 40/1CL piezo stepper for objective positioning (Piezosystem Jena).  Images were 
recorded onto a Cascade 512 electron multiplying charge coupled device camera 
(Photometrics) with 16 × 16 µm2 pixel size.  Image acquisition was controlled 
MetaMorph software (Molecular Devices, Visitron Systems Germany).  Confocal laser 
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scanning microscopy was conducted with an inverted Leica SP5 microscope (Leica 
Microsystems, Switzerland) equipped with a 63x (oil immersion, NA 1.4) objective, a 
diode laser (405 nm excitation), an argon laser (458/476/488/496/514 nm excitation), a 
helium laser (561/594/633 nm excitation).  Wide-field microscopy was carried out with 
an Olympus IX81 equipped with an 40x UPlanApo 1.00 oil objective.  Cell shapes were 
drawn by hand and mean intensities of  eGFP-fluorescence per cell was measured from 
16 bit images using NIH ImageJ (http://rsbweb.nih.gov/ij/).  Samples for analysis by 
electron microscopy (EM) were fixed in 1.5% glutaraldehyde–2% formaldehyde in 0.1 m 
cacodylate buffer (pH 7.4) for 60 min and processed for quantitative transmission EM 
(TEM) analysis as described (31).   
 
 
Data representation and statistical analyses 
 
Images were batch-processed and contrast enhanced using Adobe-Photoshop.  Data 
were represented as the mean values from triplicates of a representative experiment 
with the indicated number of cells or viruses and the standard deviation. In EM studies 
error bars indicate the standard error of the mean.  P-values were derived from 
Students-t-tests.   
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RESULTS 
 
 
CD46 and integrin but not HSPG dependent Ad35 infection of HeLa-ATCC and HK-
2 cells 
 
We first tested the receptor requirements for Ad35 for infection of HeLa-ATCC and 
human kidney (HK) 2 cells (86) by small interfering RNA (siRNA) mediated CD46 
knock-down.  A 45% or 72% reduction of the CD46 levels in HeLa-ATCC and HK2 cells 
inhibited Ad35-mediated transduction of eGFP by 50% and 78%, respectively (Fig. 1A, 
B).  This result was confirmed with an Ad35 infection-neutralizing monoclonal antibody 
directed against the short consensus repeat region (SCR) 1 of CD46 (26), which gave a 
robust dose-dependent inhibition of Ad35 but not Ad5-mediated eGFP transduction in 
HeLa-ATCC, HK-2 and Wi-38 normal lung fibroblasts (Fig. 1C,D).  This provided 
confirmatory evidence that CD46 has a major role for infection of both HeLa-ATCC and 
HK-2 cells, in agreement with earlier results from HeLa cells, human bronchial epithelial 
A549 cells and hematopoietic cells (25, 26, 30).     
 
All sequenced HAdV serotypes, except for Ad40 and Ad41 that infect the digestive tract 
(2) contain an arginine-glycine-aspartate (single amino acid code RGD) motif which 
binds integrin and is contained in extracellular matrix proteins (85).  Therefore, we 
investigated the involvement of integrins in Ad35 infection.  The RGD motif in the Ad2 
penton base had been shown to bind soluble alpha v beta 5 integrin heterodimers (12).  
The attachment of 3H-radiolabelled Ad35 to human melanoma M21L cells lacking αν 
integrins (24) was not significantly inhibited compared to αν positive M21 cells (Fig. 1E).  
Both Ad35- and Ad5-mediated eGFP transduction of M21L cells was, however, strongly 
reduced compared to M21L4 cells transfected with αν integrin cDNA or native M21 cells 
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(not shown), indicating that αν integrins support Ad35 transduction of epithelial cells 
(Fig. 1F).  A role for integrins was further strengthened by the finding that Ad35-eGFP 
expression in Wi-38 cells was significantly reduced by the soluble integrin ligand cRGD 
but not cRAD peptides (Fig. 1G).  These results were in agreement with an earlier 
report showing that integrins are involved in Ad35 transduction of human hematopoietic 
cells (72).   
 
It was recently suggested that Ad35 uses heparan sulfate proteoglycans (HSPGs) for 
attachment to CHO cells in the absence of CD46 receptors, as concluded from 
competition experiments with soluble heparin (99).  To address if HSPGs were involved 
in Ad35 infection of HeLa-ATCC or HK-2 cells, we preincubated Ad35-eGFP with 
increasing concentrations of heparin for 30 min added the mixture to HeLa-ATCC or 
HK-2 cells for 8 hours at MOI 5 and measured eGFP transgene expression.  
Unexpectedly, we did not observe any significant inhibition or stimulation of eGFP 
expression with Ad35 in both cell types (Fig. 1H, I).  We did however find a strong block 
of herpes simplex virus 1 (HSV1) mediated eGFP transduction, as reported earlier 
(107).   We concluded that HSPGs are not involved in Ad35 infection of the CD46-
positive HeLa and HK-2 cells. 
 
 
Cell type-dependent requirement of dynamin for Ad35 infection 
 
Ligation of CD46 by antibodies or Ad3 has been shown to trigger clathrin-mediated 
endocytosis or dynamin-independent macropinocytosis, depending on the degree of 
CD46 crosslinking (3, 16, 95).  By transfecting cells with dominant-negative K44A-dyn2 
tagged with mRFP for 24 hours followed by inoculation of the cells with Ad35-eGFP, we 
found that Ad35 transduction of HeLa-ATTC cells was independent of K44A-dyn2, in 
contrast to Ad5-eGFP (Fig. 2A, B).  Ad35 infection of HeLa-K cells, however, was 
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dynamin-dependent (Fig. 2C), exactly as reported for Ad3 (3).  To test if dynamin-
dependent Ad35 infection of HeLa-K cells required a clathrin related pathway, we 
overexpressed the carboxy-terminal clathrin heavy chain binding domain of AP180 (aa 
530-915), which blocks clathrin recruitment to the plasma membrane (28), and inhibits 
clathrin-mediated endocytosis (71).  It also inhibits infectious clathrin and dynamin-
dpendent endocytosis of Ad2 (31).  We found that Ad35 infection of HeLa-K cells was 
not inhibited by the C-terminal domain of AP180, unlike Ad5-eGFP transduction (Fig. 
2C).  In support of this, the dynamin inhibitor dynasore (59) had no significant effects on 
Ad35 transduction but affected Ad5 transduction of Wi-38 cells (Fig. 2D).  This 
suggested that Ad35 entry into HeLa-K cells was at least partly dependent on dynamin 
and most likely clathrin, and Ad35 entry into HeLa-ATCC and Wi-38 cells was dynamin-
independent. 
 
 
Macropinocytosis inhibitors block infectious Ad35 uptake into epithelial cells 
 
To analyze the dynamin-independent infection pathway of Ad35 we treated HeLa-
ATCC, HK-2 or Wi-38 cells with pharmacological inhibitors of macropinocytosis.  The 
classical inhibitors of macropinocytosis amiloride and its derivative 5-(N-ethyl-N-
isopropyl) amiloride (EIPA) block the sodium/proton exchangers, lead to mild 
acidification of the cytosol, alter the subcellular localization of early and late endosomes, 
and possibly raise the lumenal pH of mildly acidic organelles (29).  Likewise, millimolar 
concentrations of NH4Cl inhibit macropinocytosis (15) possibly by acidification of the 
cytosol and effects on actin dynamics (39).  We found that low micromolar 
concentrations of EIPA inhibited Ad35-eGFP transduction of HeLa-ATCC, HK-2 and Wi-
38 cells (Fig. 3A, H), similar as millimolar concentrations of NH4Cl in HeLa-ATCC, HK2 
or Wi-38 cells (Fig. 3B, and not shown).  In contrast, the proton ATPase inhibitor 
bafilomycin A1 (Baf) did not affect Ad35-eGFP transduction of HeLa or HK-2 cells, 
except at the very highest concentration of 100 nM where it decreased Ad35-eGFP 
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transduction by 10 to 25% (Fig. 3C).  It did not affect Ad35-eGFP transduction of Wi-38 
cells (not shown).  In contrast, Baf (50 nM) reduced human rhinovirus serotype 16 
infection of HeLa cells at least 20-fold compared to control cells, and blocked 
acidification of endosomal organelles (Neugebauer, Jurgeit, Greber, unpublished 
observations), suggesting that vacuolar ATPases are not required for infectious Ad35 
entry.  
 
Another class of commonly used inhibitors of macropinocytosis are actin-directed 
compounds.  Macropinosome formation involves filamentous (F)-actin, and is sensitive 
against pharmacological inhibitors (65, 68), including jasplakinolide (Jas), which 
stabilizes actin polymers, cytochalasin D (CytD), which blocks actin polymerisation at 
the barbed ends of F-actin, and the G-actin binding marine macrolide latrunculin B 
(LatB) (10, 18, 80).  Both Jas and CytD inhibited Ad35-eGFP transduction of HeLa-
ATTC and HK-2 cells in a dose-dependent manner (Fig. 3D), and LatB inhibited Ad35-
eGFP transduction of Wi-38 cells (Fig. 3I).    
 
A further requirement for macropinocytosis is the activation of calcium and 
diacylglycerol-dependent protein kinase C (PKC) family members (4, 69).  PKC 
activators induce ruffling and fluid uptake by various mechanisms involving signal 
transduction at the plasma membrane, which can be inhibited for example by the 
calcium-dependent PKC inhibitor Gö6976 (17, 63).  The treatment of HeLa-ATCC or 
HK-2 cells with Gö6976 lead to a dose-dependent inhibition of Ad35-eGFP transduction 
(Fig. 3E), similar to Ad3 which uses PKC-dependent macropinocytosis for infectious 
entry into epithelial cells (3).  Interestingly, Gö6976 had no effect on Ad35-eGFP 
transduction of Wi-38 cells suggesting a cell type-variable involvement of PKC in Ad35 
infection (data not shown).  
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An important regulator of macropinocytosis is the serine/threonine kinase p21-activated 
kinase (Pak) (20, 68).  We treated cells with the Pak inhibitor IPA-3, which allosterically 
blocks autoinhibited Pak1 and related isoforms of this kinase (19).  Ad35 transduction of 
HeLa-ATCC, HK-2 or Wi-38 cells was inhibited by IPA-3 in a dose-dependent manner, 
but not by an inactive IPA-3 related compound PIR3.5 (Fig. 3F, J).  In HeLa-ATCC or 
HK-2 cells, IPA-3 treatment specifically inhibited Ad35-eGFP without affecting Ad5-
eGFP transduction (Fig. 3G), although Ad5 transduction of Wi-38 cells was sensitive to 
IPA-3 at low micromolar concentrations (Fig. 3K). It is possible that Paks are 
overexpressed and/or hyperactivated in HeLa cells, consistent with the notion that 
signalling pathways in human tumor cells differ from those in normal tissue (23).  Ad5 
could thus circumvent Pak-1 inhibition in cancer cells by using other signalling 
pathways, which are not upregulated or absent in normal human diploid fibroblasts Wi-
38 cells.  Noteably, our earlier data showed that in cancer cells Ad2/5 depends on 
dynamin and clathrin-mediated pathways (31), activates Pak1 and triggers accessory 
Pak1-dependent macropinocytosis as indicated by RNA interference (3, 63).  We 
conclude that Ad35 transduction is sensitive to inhibition of macropinocytosis.   
 
We next used electron microscopy (EM) to determine the subcellular localization of 
Ad35 in epithelial HeLa-ATCC cells.  Time course analyses showed that Ad35 particles 
were rapidly and efficiently cleared from the plasma membrane, and more than 50% of 
the virus particles localized to the cytosol at 30 min pi (Fig. 4A, for a representative 
image, see Fig. 4B).  This indicated rapid viral uptake and endosomal escape with 
estimated half maximal times of 7 and 15 min, respectively.  EIPA, Jas and IPA-3 
delayed viral uptake into cells, and strongly reduced Ad35 localization in the cytosol 30 
min pi (Fig. 4C).  This suggested that infectious Ad35 endocytosis required sodium-
proton exchangers, dynamic F-actin and Pak1.   
 
We next analyzed if actin inhibition by Jas, or Pak1 inhibition by IPA-3 affected the 
dynamics of the plasma membrane during entry of Texas-Red-labeled Ad35 (Ad35-TR).  
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For this, we monitored the localization of eGFP-tagged human CD46 BC1 splice form in 
stably transfected Chinese Hamster ovary cells (CHO-GFP-CD46) in warm infected 
cells 5 to 15 min pi.  CHO cells are CD46-negative and resistant to Ad35 infection, 
whereas GFP-CD46 expression in these cells (CHO-CD46) mediates Ad35 transduction 
similar to CD46-expression (data not shown, and 25, 26, 30).  Control infected or 
noninfected cells showed extensive dynamics of the plasma membrane marker GFP-
CD46, including membrane ruffling and protrusions, which we call here collectively 
‘wobbling ruffles’, and frequent events of virus and CD46 colocalizations were observed 
(Fig. 5A, Suppl. Mov. 1, and Fig. 5D , Suppl. Mov. 4).  In contrast, the wobbling ruffles of 
GFP-CD46 at the plasma membrane were strongly suppressed in cells treated with Jas, 
although Ad35-TR particles readily associated with the cell periphery, and remained 
confined there throughout the observation period (Fig. 5B, and Suppl. Mov. 2).  
Likewise, the Pak1 inhibitor IPA-3 suppressed to a large extent the peripheral wobbling 
of GFP-CD46 (Fig. 5C and 5F, Suppl. Mov. 3).  Significantly, the virus particles in the 
cell periphey remained confined and were largely immobile, suggesting that IPA-3 
inhibited viral uptake into cells (see Fig. 4B).  Interestingly, viruses that were attached to 
protruding filopodia-like extensions of control or IPA-3 treated cells moved towards the 
cell body.  Such movements were not observed in Jas-treated cells where filopodia-
associated viruses remained stationary.  This is consistent with earlier results showing 
that filopodial dynamics can be blocked by Jas which freezes F-actin (10, 93).  Pak1 
apparently does not contribute to filipodial surfing of Ad35.  Whether filopodial surfing of 
Ad35 contributes to infection remains to be analyzed.   
 
 
Pak1 and CtBP1 facilitate infectious Ad35 macropinocytosis 
 
Pak1 is activated by the small GTPase Rac1 (Ras-related C3 botulinum toxin substrate 
1) during growth factor-stimulated macropinocytosis, cell adhesion and motility (41), and 
is implicated in endocytosis of interleukin-2 receptor (32), and infectious 
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macropinocytosis of Ad3 and vaccinia virus (3, 67).  The expression of dominant-
negative Rac1 (mutated threonine 17 to asparagine, T17N) inhibited the expression of 
Ad35-eGFP by about 50% (Fig. 6A, B).  Likewise, the autoinhibitory domain of Pak1 
reduced Ad35-eGFP levels by about 70% but did not affect Ad5-eGFP (Fig. 6C, D) 
supporting the notion that Pak1 is involved in species B but not species C adenovirus 
infections (3).   
 
Activated Pak1 phosphorylates the transcriptional repressor C-terminal binding protein 1 
(CtBP1) at serine 147 in the nucleus, and recruits CtBP1 into the cytoplasm (7).  There 
are two splice forms of CtBP1, a short form truncated by 11 amino acids (also called 
CtBP3/BARS) and a long form (CtBP1).  Both forms control dynamin-independent 
endocytosis (9), membrane fission and endocytic cup formation (3, 43, 56).  We found 
that the expression of dominant-negative, phosphorylation-defective CtBP1 (serine 147 
to alanine mutation, S147A), but not the phosphomimetic mutant S147D reduced Ad35-
eGFP by about 35% without affecting Ad5-eGFP (Fig. 6E, F).  These results were 
corroborated by siRNA experiments against Pak1 and CtBP1 in HeLa-ATCC and 
human alveolar epithelial A549 cells.  Knock-down of Pak1 by 65% and CtBP1 by 35% 
(measured by Western blotting in HeLa cells) reduced Ad35 transduction between 40 
and 60%, depending on the cell type, but without affecting Ad5-eGFP expression (Fig. 
6G, H, data not shown).  Control siRNAs against eGFP inhibited both Ad35- and Ad5-
eGFP expression (Fig. 6G).  Similar to epithelial cells, Ad35-eGFP transduction of 
hematopoietic K562 cells was inhibited by CtBP1 siRNA but not clathrin siRNA, 
analogous to an earlier report for Ad3 (3).  We concluded that CtBP1 supports Ad35 
infection.   
 
Both Pak1 and CtBP1 are involved in macropinocytosis, which engulfs a large amount 
of fluids into cells.  We tested if Ad35 induced the endocytic uptake of fluid phase into 
HeLa-ATCC cells.  Ad35 was bound to HeLa-ATCC in the cold, free virus washed off, 
and cells incubated in warm medium and pulsed with dextran-FITC for 5 min prior to 
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analyses of acid-washed cells for intracellular dextran by flow cytometry.  We found a 
peak of fluid-phase uptake 10 min post warming indicating that Ad35 transiently induced 
dextran uptake (Fig. 7A), similar to Ad2/5 and Ad3 (3, 40, 63, 64).  Multichannel 
confocal immunofluorescence analyses revealed that dextran and Ad35-TR positive 
endosomes contained CD46, alpha v integrins and to a lower degree also CtBP1 at 10 
min pi (Fig. 7B).  Noninfected cells did not contain detectable dextran-FITC positive 
endosomes under these pulse labeling conditions, indicating that the dextran-positive 
endosomal structures described in Fig. 7B were virus induced (Fig. S1).  Quantitative 
analyses using wide field fluorescence microscopy showed that 91% of the dextran-
filled vesicles in Ad35 infected cells were positive for CD46, essentially all were alpha v 
integrin positive, and 77% were positive for CtBP1 (Fig. S2).   
 
Transmission electron microscopy showed that Ad35 particles were in large endosomes 
10 min pi several micrometers in diameter (Fig. 7C).   These endosomes contained 
cointernalized BSA-gold.  To test if macropinocytosis contributed to the levels of BSA-
gold in Ad35 positive endosomes, we compared the amounts of BSA-gold in 
endosomes containing Ad2-ts1.  Ad2-ts1 enters cells by dynamin and clathrin-mediated 
endocytosis in the absence of macropinocytic stimulation (31, 40).  More than 90% of 
the endosomal Ad35 particles were in BSA-gold positive vesicles, whereas about 65% 
of the Ad2-ts1 particles were in gold-positive endosomes (Fig. 7D).  We found that 
about 60% of the total BSA-gold particles were in Ad35-positive endosomes, whereas 
about 15% of the total BSA-gold were in Ad2-ts1 positive endosomes. This strongly 
supported the conclusion that Ad35 was predominantly in fluid-enriched endosomes 10 
min pi.  Together the data indicate that Ad35 induces CD46 and integrin-dependent 
macropinocytosis for infectious uptake into epithelial HeLa-ATCC and kidney HK-2 cells 
as well as hematopoietic cells (see Fig. 8 for a schematic overview).   
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DISCUSSION 
 
Adenoviruses cause infectious disease and significant health problems across the 
world.  Therapeutic forms of adenoviruses are increasingly developed to treat human 
diseases, including cancer and immune disorders (92, 98).  Research in the past years 
has shown that both virulent and therapeutic viruses strongly depend on host factors for 
eliciting therapeutic or disease phenotypes (for overviews, see 47, 92, 94).  Here, we 
analyzed the early interactions of Ad35 with cultured human cells, and show that they 
involve macropinocytosis of CD46-associated Ad35 particles.  Unlike an earlier study in 
CHO cells (99), we found no requirement of heparan sulfate proteoglycans for Ad35 
infection of HeLa or human kidney HK-2 cells, which emphasizes the importance of 
CD46 for infectious entry of Ad35 (30).  This is in line with earlier findings showing that 
the species B1 Ad3 uses macropinocytosis for infectious uptake into epithelial and 
hematopoietic cells (3).  Noteably, Ad35 is one of several species B human 
adenoviruses which have been shown to bind with their fiber knobs to CD46 (25, 26, 30, 
79).  Other CD46-tropic adenoviruses include Ad3 (95), Ad11 (91), Ad14, Ad16, Ad21 
and Ad50 (30), and also the species D Ad37 (106) and Ad49 (54).  It is possible that 
members of the species B HAdVs use CD46 with different affinities or by unknown 
mechanisms, or bind to additional receptors.   
 
In addition to binding to the species B HAdVs, CD46 also binds the Edmonston strain of 
measles virus (22, 75), human herpes virus 6 (89), bovine viral diarrhea virus (62), and 
various bacteria including uropathogenic E. coli (55, 57).  The selection of CD46 as a 
receptor for numerous pathogens suggests that there are advantages for pathogens to 
bind to CD46, e.g. dampening or suppression of innate immune responses (44, 77).  
The ubiquitously expressed human CD46 is involved in the control of complement lysis 
and inhibition of T cell effector functions (6, 45).  The cytoplasmic splice variant 1 of 
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CD46 controls the induction of autophagic degradation (42), which can lead to 
enhanced presentation of antigenic peptides to major histocompatibility complexes of 
the class II and promote adaptive immune responses and inflammation (90).  Although 
both cytoplasmic splice variants 1 and 2 of CD46 have been found to bind Ad3 and 
Ad35 (30, 95), it is unknown if binding of HAdVs to CD46 induces autophagy. 
 
Our data here indicate that Ad35 induced infectious CD46-dependent macropinocytosis, 
similar to Ad3 in epithelial cells (3), and this could be related to integrin-dependent Ad35 
infection of hematopoietic cells (72).  The pathway that we delineate for Ad35 infection 
involves alpha v integrins, independent of clathrin-mediated endocytosis, as concluded 
from insensitivity against dynamin inhibition by dynasore, dominant-negative constructs 
or siRNA in HeLa-ATCC, Wi-38 human lung fibroblasts, A549 cells or hematopoietic 
K562 cells.  Interestingly, K44A-dynamin inhibited the transduction of Ad35 in HeLa-K 
cells, a variant of HeLa-ATCC, but infection of these cells was not affected by the C-
terminal fragment of AP180, which binds to clathrin and blocks clathrin-mediated 
endocytosis (28).  This is similar to Ad3 transduction reported earlier (3).  Since 
dynamin interference inhibited the uptake of transferrin, a classical ligand for clathrin-
mediated endocytosis, to a similar extent in both HeLa-ATCC and HeLa-K cells, we 
speculate that in certain cell types, such as HeLa-K, dynamin supports Ad3 and Ad35 
transduction at the level of endosomal trafficking (51, 52).  This speculation could be 
supported by an earlier finding that the clathrin binding protein CALM (clathrin assembly 
lymphoid myeloid) is required for infection with wild type Ad2 but not the endosomal 
escape-defective mutant Ad2-ts1 (40).   
 
The requirements for infectious endocytosis of Ad35 into human epithelial cells closely 
reflect those for macropinocytosis, as indicated by drug sensitivity and morphological 
analyses at the level of light microscopy and EM.  We found a strong but cell-type 
dependent requirement of Ad35 transduction for PKC, and a strong cell-type 
independent requirement for the sodium/proton exchanger, actin and Pak1 in HeLa-
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ATCC, HK-2 and Wi-38 cells, as well as the actin modulator Rac1 and the Pak1 effector 
CtBP1 in HeLa-ATCC and HK-2 cells.  CtBP1 is commonly acting as a transcriptional 
repressor and membrane organizer (11, 14).  Ad35 colocalized with its receptors CD46 
and αν-integrins in dextran-filled macropinosomes and was associated with dynamic 
GFP-CD46 clusters early in infection.  These endosomes were positive for CtBP1, 
unlike noninfected cells, suggesting that CtBP1 was recruited to Ad35-positive 
membrane domains, possibly from the nucleus upon phosphorylation by Pak1 (7).  This 
was supported by the finding that dominant-negative phosphorylation defective CtBP1 
inhibited Ad35 transduction.  Since macropinocytosis has been implicated in immune 
suppression, for example in the uptake of apoptotic bodies (1), it is possible that 
Pak1/CtBP1 dependent macropinocytosis leads to transcriptional depression, and 
silences immune responses.   
 
Together, our results provide supportive evidence that crosslinking of CD46 by 
multivalent Ad35 particles leads to the formation of macropinocytic vesicles, similar to 
crosslinking induced by anti-CD46 antibodies or measles virus which triggered the 
formation of pseudopodia and macropinocytic engulfment of CD46 (16).  This indicates 
that macropinocytosis is an infectious uptake route exploited by an increasing number 
of pathogens, and has implications for gene delivery and vaccination strategies. 
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FIGURE LEGENDS 
 
Fig. 1: CD46 and alpha-v-integrins are required for Ad35 infection but not HSPG.  
 
(A) HeLa-ATCC (left) or HK-2 (right) were transfected with 20 nM siRNAs against  
CD46, GFP or non-silencing scrambled (scr) for 72 h and infected with Ad35-eGFP 
(MOI 5) or Ad5-eGFP (MOI 5) for 8 h, followed by Safire fluorescence analysis.  (B) 
Quantification of knock-down efficiency by Western blots against CD46, normalized 
against calnexin.  (C) HeLa-ATCC (left) or HK-2 (right) or Wi-38 cells (panel (D)) were 
preincubated with an inhibiting antibody against CD46 (MEM-258) in the cold for 30 min, 
and infected for 8 h or 15 h, respectively.  (E) 3H-Ad35 was bound to human melanoma 
M21L cells lacking alpha v integrin or M21 alpha v integrin positive cells.  (F) M21L or 
M21 cells were infected with Ad35-eGFP or Ad5-eGFP, and analyzed by Safire 
fluorescence analyses.  (G) Wi-38 cells were preincubated with cRGD or cRAD 
peptides in the cold for 30 min and infected with Ad35-eGFP for 15 h.  (H, I) Ad35-eGFP 
(MOI 5) or HSV-1-eGFP (MOI 5) were preincubated for 30 min with different 
concentrations of heparin as indicated followed by inoculation of HeLa-ATCC or HK-2 
cells for 8 h, and infection analyses with a Safire2 plate reader after normalization to the 
cell numbers determined by DAPI staining (see Materials and Methods).  Note that 
Ad35-eGFP transduction was not affected, whereas HSV-1-eGFP transduction was 
strongly reduced in both cell lines. 
 
 
Fig. 2: Cell type specific requirements of dynamin.  
 
HeLa-ATCC or HeLa-K cells were transfected with dominant-negative mRFP-Dyn2-
K44A, mRFP-Dyn2-wt or mRFP for 24 h, and infected with Ad35-eGFP or Ad5-eGFP 
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(MOI 5) for 8 h.  (A) Representative images of transfected and infected HeLa-ATCC, 
fixed and recorded for mRFP and GFP fluorescence in a wide-field microscope.  (B) 
NIH ImageJ quantification of total fluorescence intensities.  (C) HeLa-K cells were 
transfected as in (A) and in addition with the carboxy-terminal domain of AP180, 
infected and assayed by FACS.  Dominant-negative K44A-Dyn2 inhibited both Ad35-
eGFP and Ad5-eGFP, whereas carboxy-terminal domain of AP180 had no effects on 
Ad35-eGFP but inhibited Ad5-eGFP by 40%.  (D) Dynasore independent transduction of 
Wi-38 cells by Ad35-eGFP (left) and dynasore-dependent transduction by Ad5-eGFP 
(right panel) in the absence of cell toxicity indicated by cell number measurements 
shown with grey line graphs, with 100% representing noninfected non-drug treated 
conditions.  
 
 
Fig. 3: Inhibitors against Pak1, PKC, sodium/proton exchanger and actin reduce 
Ad35-eGFP transduction.  
 
HeLa-ATCC and HK-2 were preincubated with indicated concentrations of drugs for 30 
min, and infected with Ad35-eGFP for 8 h.  Cells were analyzed on a Safire2 plate 
reader and eGFP intensities normalized to the DAPI signal of the cell nuclei 
representing cell numbers.  Results for EIPA are shown in panel (A), NH4Cl in (B), 
bafilomycin (Baf) in (C), jasplakinolide (Jas) and cytochalasin D (CytD) in (D), the PKC 
inhibitor Gö6976 in (E), and the Pak1 inhibitor IPA-3 and its inactive derivative PIR3.5 in 
(F) and (G) for both Ad35-eGFP and Ad5-eGFP, respectively.  Panels H-K show results 
with macropinocytic interference in Wi-38 cells transduced with Ad35-eGFP or Ad5-
eGFP.  Note the absence of significant cell toxicity as indicated by cell number 
measurements shown with grey line graphs, with 100% representing noninfected non-
drug treated conditions.  
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Fig. 4: EM analysis of Ad35 entry into HeLa-ATCC cells 
 
(A) Cells on glass coverslips were incubated with double CsCl purified Ad35 particles 
for 90 min in the cold at high MOI of 5000, washed extensively, warmed to 37°C in 
growth medium containing 0.2% BSA for indicated times, fixed and processed for 
quantitative transmission EM analyses of virus particles at the plasma membrane, in 
endosomes and in the cytosol.  Half maximal time points for endocytic uptake and 
penetration into the cytosol were 7 and 15 min, respectively.  (B) Electron micrograph of 
an Ad35-infected HeLa-ATCC cell 30 p.i.. Stars depict virus particles in the cytosol, 
arrows particles in endosomes and arrowheads at the plasma membrane.  (C) The 
same experiment was repeated with cells treated or not treated with the sodium/proton 
inhibitor EIPA (50 µM), the F-actin stabilizer Jas (300 nM) or the Pak1 inhibitor IPA-3 
(25 µM), and infected for 30 min.  
 
 
Fig. 5: Ad35-TR is associated with GFP-CD46 clusters early in infection.  
 
Stably transfected CHO-GFP-CD46 cells were infected with Ad35-TR (1 µg/ml) for 5 
min, and recorded in a spinning disc confocal microscope equipped with a warm 
chamber at 37° C from 5 min to 15 min p.i. at acquisition frequency of 0.06 Hz.  Panel 
(A) shows a control cell with extended wobbling of GFP-CD46 membrane domains and 
frequently overlapping signals of CD46 and Ad35-TR.  Panel (B) shows a cell pretreated 
with 300 nM Jasplakinolide (Jas) for 30 min and (C) depicts a cell pretreated with 25 µM 
IPA-3.  Time stamps are in min (‘).  (D) Analyses of GFP-CD46 wobbling ruffles with 
schematic drawing shown in (E) of an untreated, infected cell with two zoom-in views 
marked * and ** with the corresponding time stamp min (‘) and seconds (‘’) p.i..  (F) 
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Quantitative boxplot analyses of wobbling ruffles in control noninfected cells, infected 
cells and infected cells treated with Jas or IPA-3.  
 
 
Fig. 6: Rac1, Pak1 and CtBP1 are required for Ad35-eGFP transduction of HeLa-
ATCC cells.  
 
Cells were transfected with indicated constructs for 24 h, and infected for 8 h, fixed, 
recorded in a wide-field microscope and analyzed with ImageJ.  (A) Representative 
images of dominant-negative mRFP-T17N-Rac1 or Rac-wt transfected cells.  (B) 
Quantification of the mean fluorescence intensity per cell with indicated number of cells 
(n).  (C) Representative images of Pak1-autoinhibitory domain (AID) transfected cells 
infected with Ad35-eGFP or Ad5-eGFP, and quantification of the mean fluorescence 
intensity per cell (D).  (E) Representative images of phosphorylation defective CtBP1-
S147A transfected cells infected with Ad35-eGFP or Ad5-eGFP.  (F) Quantification of 
the mean fluorescence intensity of GFP expression per cell in wild type (wt) CtBP1, 
S147A and S147D CtBP1 mutants.  (G) Cells were transfected with 50nM siRNA 
against indicated targets for 72 h, infected for 8 h and analyzed with Safire2.  Cell 
numbers were normalized to DAPI signal.  (H) Knock-down quantification of Pak1 and 
CtBP1 by Western blot, normalized against calnexin.  (I) A549 cells were transfected 
with 20 nM siRNA against CtBP1, Pak1 or dynamin2 for 48 h, infected with Ad35-eGFP 
(16h) and analyzed by flow cytometry.  K562 cells were transfected with 20 nM siRNA 
against CtBP1 or clathrin heavy-chain (CHC) as described (3), infected with Ad35-eGFP 
(16h) and analyzed by flow cytometry. 
 
 
Fig. 7: Ad35-TR induced fluid phase uptake and colocalizes with CD46, integrins 
and CtBP1 in dextran-filled macropinosomes.  
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(A) Ad35 (2 mg/ml) was cold bound to HeLa-ATCC cells for 1 h. Cells were washed, 
pulsed with dextran-FITC (0.5 mg/ml) in warm medium (37°C) containing BSA 5 min 
before the indicated time points, and prepared for flow cytometric analysis.  (B) Cells 
were cold-bound with Ad35-TR (1 µg/ml) for 1 h, washed and incubated at 37°C in the 
presence of dextran-FITC (0.5 mg/ml) for 10 min, fixed, stained for the indicated 
antigens and analyzed by confocal laser scanning microscopy with corresponding 
differentail interference contrast (DIC) images.  Fluorescence images represent single 
sections, and inlets are magnifications of the white boxed areas.  (C) Electron 
micrograph of an Ad35 infected HeLa-ATCC cell (cold synchronized infection at MOI 
5000), pulsed in the presence of BSA-nano-gold for 10 min.  Arrowheads indicate BSA-
gold particles, black arrows show Ad35 in BSA-gold positive endosomes, white arrows 
show virus particles in endosomes without BSA-gold, small triangles indicate viruses at 
the PM, and stars depict Ad35 particles in the cytosol.  (D) Quantification of (C), 
including HeLa-ATCC cells inoculated with Ad2-ts1 which is defective in endosomal 
escape.  N indicates number of virus particles and n number of BSA-gold particles.  
 
 
Fig. 8: Schematic model of infectious macropinocytosis of Ad35 in human 
epithelial cells.  
 
Ad35 binds to CD46 and alpha v-integrins independently of heparan sulfate 
proteoglycans (HSPGs).  Ad35 is internalized in an actin, Rac1, Pak1, CtBP1 and PKC 
dependent manner and localizes to dextran-filled vesicles with its receptors CD46, 
alpha v integrins and also CtBP1.  Ad35 escapes to the cytosol by an unknown 
mechanism and traffics to the nucleus for infection.  
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Supplemental figures 
 
Fig. S1: Immunofluorescent stainings of CD46, αν-integrins or CtBP1 in non-
infected cells.  
HeLa-ATCC were incubated with 0.5 mg/ml Dextran-FITC for 10 min at 37°C in the 
absence of virus.  Cells were fixed, and processed for immunofluorescence analyses as 
indicated in Fig. 7B.  Images represent single sections. 
 
Fig. S2: Quantification of Ad35 induced dextran-FITC filled vesicles containing 
CD46, αν-integrins and CtBP1.  
Dextran-FITC uptake was induced by Ad35 with a 10 min pulse as described in Fig. 7A. 
Samples were fixed and analyzed by wide-field microscopy.  Panel (A) displays 
representative sample images for all three marker proteins.  Panel (B) shows the 
quantification of dextran-FITC positive vesicles for the presence of CD46 (n=70), αν-
integrins (n=63) or CtBP1 (n=61), displayed as percentage of macropinosomes positive 
for CD46, αν-integrins or CtBP1 by boxplot analyses.  
 
 
Supplemental movies S1-S4: Dynamics of eGFP-CD46 and Ad35-TR in control 
cells and cells treated with Jasplakinolide (Jas) or IPA-3.  
 
Stably transfected CHO-GFP-CD46 cells were infected with Ad35-TR (Texas Red, 1 
µg/ml) for 5 min and recorded in a spinning disc confocal microscope equipped with a 
warm chamber at 37° C from 5 min to 15 min p.i. with an acquisition frequency of 0.06 
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Hz.  Supplemental movie 1 shows control cells infected with Ad35-TR.  Supplemental 
movie 2 shows cells treated with Jas (300 nM), and supplemental movie 3 shows cells 
treated with IPA-3 (25 µM).  Supplemental movie 4 shows GFP-CD46 wobbling ruffles 
of infected control cells 5 to 20 min pi.  Still images of these movies are shown in Fig. 
5A-D.   
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